Please select the eligibility criteria that correspond to the clinical trial below.
Title: Use of Volatile Anesthetics for Long-Term Sedation In Critically Ill Patients
Brief Summary: Heavy sedation or sleep is a common problem within the intensive care unit (ICU) using our standard intravenous medications. This commonly leads to confusion, low blood pressure, slow wake up and removal of the artificial breathing tube (extubation), which prolongs ICU stay. Using inhaled volatile anesthetic agents are likely to improve these patient outcomes. This unique project is the first North American study looking at using volatiles for patients who need longer-term ICU sedation. This project has excellent potential at lowering these complications and improving quality of care, which will lower patient ICU stay and healthcare costs.


Options:
A: Inclusion Criteria:

* 18 years of age or over
* Mechanically ventilated, with anticipated need for MV ≥48 hrs
* ICU team has decided to initiate continuous sedative/analgesic infusion(s)
* informed consent from patient and/or SDM

Exclusion Criteria

* Admission after resuscitation from cardiac arrest
* Traumatic brain injury
* Currently receiving neuromuscular blocking agents
* Allergy to midazolam and lorazepam
* Lack of commitment to aggressive treatment
* Previous enrolment in SLEAP, or current enrolment in related trial
B: Inclusion Criteria:

* adult ICU patients expected to be ventilated \> 48 hours

Exclusion Criteria:

* age \< 18 years
* history of malignant hyperthermia
* propofol infusion syndrome
* evidence of raised intracranial pressure
* 6-month mortality risk from pre-existing condition \> 50%
* lack of commitment to maximal treatment
* pregnant
* NebulizedFlolan
* tidal volume \<350ml
* patients on one lung ventilation
C: Inclusion Criteria:

* Patients in first or subsequent hematological or molecular relapse of APL
* Persistence of a positive PCR or no hematological complete remission (CR) after first line therapy
* No complete hematological remission after first line therapy
* Age over 18 years
* No upper age limit
* Informed consent of the patient

Exclusion Criteria:

* Absolute QTc-interval prolonged over 460 msec before therapy (normal electrolytes, no other drugs prolonging the QT-interval)
* Heart failure New York Health Association grade III and IV
* Renal or hepatic failure World Health Organization grade \>= III
* Pneumonia with hypoxemia
* Uncontrolled sepsis
* Pregnancy and lactation period
* Secondary malignancy, which will have major influence on the prognosis
* Expected noncompliance
* No informed consent of the patient.
D: Inclusion Criteria

1. Patients intubated and mechanical ventilated for \< 72 hours
2. Age \> 18 years
3. Baseline independent functional status as assessed by a Barthel Index score \> 70 collected from a proxy reflecting baseline health 2 weeks prior to critical illness

Exclusion Criteria

1. Rapidly evolving neurological/neuromuscular disease
2. Cardiac arrest
3. Irreversible conditions with six month mortality estimated at \> 50%
4. Elevated intracranial pressure
5. Multiple absent limbs (precluding complete musculoskeletal examination)
6. Enrollment in another trial

Answer: B